Although little is known about its exact physiological function, CD52 has shown to be a promising target for several immune system-mediated diseases, such as multiple sclerosis (MS), autoimmune inflammatory neurodegenerative diseases, allergic asthma, and lymphocytic leukemia (Shafiei-Jahani et al., 2021). This evidence concerns the gene CD52 and myeloid sarcoma.